TMC Acquisition LLC dba Tailor Made Compounding
Has TMC Acquisition LLC dba Tailor Made Compounding received an FDA warning letter about GLP-1 drugs?
No FDA warning letter to TMC Acquisition LLC dba Tailor Made Compounding naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 2 drug recall reports for it naming semaglutide, the latest initiated Mar 7, 2022.
FDA records in this index name TMC Acquisition LLC dba Tailor Made Compounding on Mar 7, 2022.
- Type named in FDA records
- Not stated
- FDA warning letters
- 0
- Drug recall reports
- 2
- Drugs named
- Semaglutide
- Latest record
- Mar 7, 2022
FDA warning letters
No FDA warning letters in this index.
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Mar 7, 2022 | Semaglutide/Cyanocobalamin 5mg/0.2mg/ml, 2ml-vial, Refrigerate, Tailor Made Compounding | Lack of Assurance of Sterility | Class II | Ongoing | D-1225-2022 |
| Mar 7, 2022 | Semaglutide/Cyanocobalamin 2mg/0.4mg/ml, 1mL-vial, Refrigerate, Tailor Made Compounding | Lack of Assurance of Sterility | Class II | Ongoing | D-1224-2022 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.